Revolutionizing Advanced Ovarian Cancer Therapy: A Focus on the PD-1/PD-L1 Pathway
DOI:
https://doi.org/10.37547/ajbspi/Volume03Issue10-01Keywords:
Advanced ovarian cancer, immune checkpoint inhibitors, programmed cell death protein 1Abstract
This comprehensive review delves into the cutting-edge advancements in the treatment landscape of advanced ovarian cancer, with a specific focus on the programmed cell death protein 1 (PD-1) and its ligand PD-L1 pathway. Ovarian cancer, often diagnosed at advanced stages, poses significant challenges due to limited effective treatment options. The emergence of immune checkpoint inhibitors targeting the PD-1/PD-L1 pathway has sparked new hope for improved outcomes. This review explores the mechanistic basis of PD-1/PD-L1 interactions, outlines the evolving clinical trials assessing immune checkpoint inhibitors, and discusses the clinical significance of these therapies in reshaping the therapeutic paradigm for advanced ovarian cancer.
References
Bulowski RM, Ozole RF, Markman M (2007) The management of ecurrent ovarian cancer. Siminal Oncol 34: S1-S15.
Ozols RF (2006) Challenges of chemotherapyin ovarian cancer. Ann Oncol 17(Suppl 5): v181-v187.
Zhang L, Congo-GarciaJR, Katsaros D, Gimutty PA, Masssobro M, et al (2003) Intratumoral T cell, recurrence and survivalin epithelial ovarian cancer. N Engl J Med 348(3): 203-213.
Kempsi J, Karyamodi L, Bohrens MD, Erskine CL, HartmannL, et al. (2011) Tumor infiltrating programmed deathreceptor1-dendritic cellsmediate immune suppression in ovarian cancer. J Immunol 186(2): 6905-6913.
Lhou IC, Ganesan P, A mstrong TD, Jaffer EM (2008) Effective depetion of regulatory Tcellsallows the recruitment of mesothelin-specific CD8+Tcells to the antitumor response against a mensothelian expressing mouse pancreatic adenocarcinoma. Clin Transl Sci 1(3): 28-39.
Wang B, Kurowa JM, HeLZ, Charalambous A, Keler T, et al. (2009) The human cancerantigen mesothelin is more efficiently presented to the mouse immune system when targeted to the DEC205/CD205 receptor on dendritic cells. Ann NY Acad Sci 174: 6-17.
Kan ME, Butte MJ, Freeman GJ, Sharpe AH (2008) PD1and its ligand in cancer and immunity. Ann Rev Immunol 26(5): 677-704.
Freeman GJ, Wherry EJ, Ahmed R, Sharpe AH (2006) Reinvigorating exhaustivre HIV specific Tcells via PD1-PDL1 blockade. J Exp Med 203(10): 2223-2227.
Wilke CM, Kryczek C, Zhou W (2011) Antigen presenting cells (APC) Subsetsin ovarian cancer. Int Rev Immunol 30(2-3): 120-126.
Nolon B, Opel S, Del-Pozzo F, Soldon C, Zilo S, et al. (2011) Chemokine nitration prevents intratumoral infiltration of antigen specific T cells. J Exp Med 208(10): 1949-1962.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Mandeep Kaur
This work is licensed under a Creative Commons Attribution 4.0 International License.
